cancerguard.com
CancerGuard.com presents a new blood test that can find warning signals linked to many cancers, but the test should support standard screening rather than replace it.
What is CancerGuard?
CancerGuard is a multi-cancer early detection blood test made by Exact Sciences, the company behind Cologuard.
The test looks for changes in tumor DNA and levels of proteins associated with cancer.
It covers signals linked to more than 50 cancer types and subtypes, including pancreatic, lung, liver, ovarian, stomach, and esophageal cancers.
These hard-to-find cancers are the test’s strongest use case because most do not have a routine screening program for people without symptoms.
CancerGuard is intended for adults aged 50 to 84 who have not received a cancer diagnosis during the past three years.
It is not intended to screen for breast cancer, prostate cancer, or precancerous growths.
How does the test work?
A doctor can order the test, or a person can request it online and complete a health review with a licensed telehealth provider.
The customer then visits a supported lab, arranges an eligible home visit, or has blood drawn at a medical office.
No fasting or special preparation is required.
The laboratory studies the blood for several biological signals and produces either a positive or negative result in about two weeks.
A positive result means cancer signals were found, but it does not prove that the person has cancer.
A negative result means no signal was found, but it does not prove that the person is cancer-free.
The official process page says that people with positive results may receive help from a care navigator to arrange imaging and other follow-up care.
How accurate is CancerGuard?
A test-development study reported 64.1% overall sensitivity and 97.4% specificity across 19 studied cancer types, excluding breast and prostate cancer.
In simple terms, the test detected about 64 of every 100 cancers represented in that study and missed about 36.
Its 97.4% specificity means that roughly 2.6 of every 100 people without cancer could receive a positive result under similar study conditions.
CancerGuard showed about 68% sensitivity across six especially deadly cancers: pancreatic, lung, liver, esophageal, stomach, and ovarian cancer.
It found more than one-third of stage I and stage II cancers, according to Exact Sciences’ launch data.
These results came from case-control studies that compared people already known to have cancer with people believed to be cancer-free.
Exact Sciences warns on its provider information page that performance in normal clinical use may be lower.
This distinction matters because a screening population contains far fewer people with cancer than a carefully selected study group.
Can CancerGuard diagnose cancer?
CancerGuard cannot diagnose cancer, identify its exact location, or report its stage.
A positive result may lead to CT scans, other imaging, specialist visits, or a biopsy before doctors can confirm what caused the signal.
These later steps can bring added cost, worry, radiation exposure, and occasional medical risk.
A negative result must not be used as a reason to skip a mammogram, colonoscopy, cervical screening test, PSA discussion, or recommended lung scan.
The American Cancer Society says multi-cancer tests may eventually add value, but more research is needed before they can be recommended for widespread screening of people without symptoms.
Is CancerGuard approved by the FDA?
CancerGuard has not been cleared or approved by the US Food and Drug Administration.
It is sold as a laboratory-developed test performed in a laboratory operating under CLIA and CAP requirements.
These laboratory standards cover testing quality, but they are not the same as an FDA review proving that population-wide screening improves health outcomes.
Researchers still need stronger real-world evidence showing whether testing reduces late-stage cancer, lowers cancer deaths, and creates more benefit than harm.
How much does CancerGuard cost?
The test currently costs $689 and is generally not covered by health insurance.
HSA or FSA funds may be accepted when the customer meets the relevant account rules.
The price includes the test, access to an optional telehealth consultation, and the result, but it may not cover every scan or procedure required after a positive finding.
The website also sells gift cards, although a medical screening decision is usually best made with the recipient and their doctor rather than given as a surprise.
Who should consider CancerGuard?
The test may interest an adult aged 50 to 84 with a strong family history, past smoking, obesity, heavy alcohol use, or concern about cancers that lack normal screening tools.
It may be less suitable for someone who cannot access or afford the follow-up work that a positive result could start.
Pregnant people and those diagnosed with cancer during the previous three years fall outside its stated intended population.
Anyone with pain, bleeding, unexplained weight loss, a new lump, or another possible cancer symptom needs a clinical evaluation rather than a screening test bought online.
CancerGuard is best viewed as an optional extra layer for a carefully informed patient, not as a complete cancer check or a source of guaranteed peace of mind.